Detalhe da pesquisa
1.
Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD.
Neurobiol Dis
; 179: 106050, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809847
2.
Deceleration of the neurodegenerative phenotype in pyroglutamate-Aß accumulating transgenic mice by oral treatment with the Aß oligomer eliminating compound RD2.
Neurobiol Dis
; 124: 36-45, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30391539
3.
Pyroglutamate-Modified Amyloid-ß(3-42) Shows α-Helical Intermediates before Amyloid Formation.
Biophys J
; 112(8): 1621-1633, 2017 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-28445753
4.
Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic ß-Amyloid Oligomers.
Pharm Res
; 33(2): 328-36, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26381279
5.
The Avidity of Autoreactive Alpha-Synuclein Antibodies in Leucine-Rich Repeat Kinase 2 Mutation Carriers Is Not Altered Compared to Healthy Controls or Patients with Parkinson's Disease.
Biomolecules
; 13(9)2023 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37759704
6.
Effects of a Multimerized Recombinant Autoantibody Against Amyloid-ß.
Neuroscience
; 463: 355-369, 2021 05 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958140
7.
Role of Hydrophobicity and Charge of Amyloid-Beta Oligomer Eliminating d-Peptides in the Interaction with Amyloid-Beta Monomers.
ACS Chem Neurosci
; 9(11): 2679-2688, 2018 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29893543
8.
Relevance of N-terminal residues for amyloid-ß binding to platelet integrin αIIbß3, integrin outside-in signaling and amyloid-ß fibril formation.
Cell Signal
; 50: 121-130, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29964150
9.
LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF.
Cell Signal
; 46: 32-42, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29476963
10.
Inhibition of amyloid Aß aggregation by high pressures or specific d-enantiomeric peptides.
Chem Commun (Camb)
; 54(26): 3294-3297, 2018 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29537428
11.
In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease.
J Alzheimers Dis
; 64(3): 859-873, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29966196
12.
Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease.
Eur J Pharm Sci
; 114: 93-102, 2018 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29225107
13.
Biophysical insights from a single chain camelid antibody directed against the Disrupted-in-Schizophrenia 1 protein.
PLoS One
; 13(1): e0191162, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29324815
14.
Aß oligomer eliminating compounds interfere successfully with pEAß(3-42) induced motor neurodegenerative phenotype in transgenic mice.
Neuropeptides
; 67: 27-35, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29273382
15.
Optimization of d-Peptides for Aß Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic Aß Oligomers.
ACS Chem Neurosci
; 8(9): 1889-1900, 2017 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28581708
16.
The Aß oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology.
Sci Rep
; 7(1): 16275, 2017 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29176708
17.
Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aß Species.
ACS Chem Neurosci
; 7(8): 1088-96, 2016 08 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27240424
18.
Optimization of the All-D Peptide D3 for Aß Oligomer Elimination.
PLoS One
; 11(4): e0153035, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27105346
19.
Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease.
Eur J Pharm Sci
; 89: 31-8, 2016 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27086111
20.
Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease.
PLoS One
; 10(6): e0128553, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26046986